Omega-3 polyunsaturated fatty acids in sarcopenia management: A network meta-analysis of randomized controlled trials
Ageing Research Reviews · 2023-09 · 90 · 102014
DOI: 10.1016/j.arr.2023.102014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2023-09. Verfasst von Ping-Tao Tseng und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan; Department of Psychology, College of Medical and Health Science…. Hauptthemen laut MEDLINE: Sarcopenia, Fatty Acids, Omega-3. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: China Medical University, Taiwan, Maudsley Charity, China Medical University Hospital.
Abstract (Originalsprache)
Sarcopenia frequently occurs with aging and leads to major adverse impacts on activities of daily living and quality of life in elderly individuals. Omega-3 polyunsaturated fatty acid (omega-3 PUFAs) supplements are considered promising therapeutic agents for sarcopenia management; however, the evidence remains inconsistent. We reviewed randomized controlled trials (RCTs) about omega-3 PUFA supplementation in patients with sarcopenia or in those at high risk for sarcopenia. Network meta-analysis (NMA) procedures were conducted using a frequentist model. The primary outcomes were (1) upper-extremity muscle strength and (2) lower-extremity physical function. The NMA of 16 RCTs showed that the high-dose (more than 2.5 g/day omega-3 PUFAs) group yielded the greatest improvement in both upper-extremity muscle strength and lower-extremity physical function [compared to placebo/standard care groups, standardized mean difference (SMD)= 1.68, 95% confidence interval (95%CI)= 0.03-3.33, and SMD= 0.73, 95%CI= 0.16-1.30, respectively], and the effects were reaffirmed in subgroup analyses of placebo-controlled RCTs or those excluding concurrent resistance training programs. None of the investigated omega-3 PUFAs supplementation was associated with significantly increased skeletal muscle mass, fat mass, or overall body weight. Our findings provide a basis for future large-scale RCTs to investigate the dose effects and clinical application of omega-3 PUFA supplementation in sarcopenia management. TRIAL REGISTRATION: The current study was approved by the Institutional Review Board of the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (TSGHIRB No. B-109-29) and registered in PROSPERO (CRD42022347161).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan; Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan; Prospect Clinic for Otorhinolaryn…
- Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan; Department of Internal Medicine, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
- Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan; Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, Taiwan.
- Department of Psychology, College of Medical and Health Science, Asia University, Taichung, Taiwan; Clinical Psychology Center, Asia University Hospital, Taichung, Taiwan; Center for Prevention and Treatment of Internet…
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK; Facult…
- Neuroscience and Brain Disease Center, China Medical University,Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Förderung
- China Medical University, Taiwan
- Maudsley Charity
- China Medical University Hospital
- King's College London
- National Health Research Institutes
- Tainan Municipal An-Nan Hospital
- King’s College London
- Ministry of Education
Zitieren
APA
Tseng, P. T., Zeng, B. Y., Zeng, B. S., Liao, Y. C., Stubbs, B., Kuo, J. S., Sun, C. K., Cheng, Y. S., Chen, Y. W., Chen, T. Y., Tu, Y. K., Lin, P. Y., Hsu, C. W., Li, D. J., Liang, C. S., Suen, M. W., Wu, Y. C., Shiue, Y. L., & Su, K. P. (2023). Omega-3 polyunsaturated fatty acids in sarcopenia management: A network meta-analysis of randomized controlled trials. Ageing Research Reviews, 90, 102014. https://doi.org/10.1016/j.arr.2023.102014
Vancouver
Tseng PT, Zeng BY, Zeng BS, Liao YC, Stubbs B, Kuo JS, et al. Omega-3 polyunsaturated fatty acids in sarcopenia management: A network meta-analysis of randomized controlled trials. Ageing Research Reviews. 2023;90:102014. doi:10.1016/j.arr.2023.102014
BibTeX
@article{Tseng2023,
author = {Tseng, Ping-Tao and Zeng, Bing-Yan and Zeng, Bing-Syuan and Liao, Yu-Chi and Stubbs, Brendon and Kuo, John S and Sun, Cheuk-Kwan and Cheng, Yu-Shian and Chen, Yen-Wen and Chen, Tien-Yu and Tu, Yu-Kang and Lin, Pao-Yen and Hsu, Chih-Wei and Li, Dian-Jeng and Liang, Chih-Sung and Suen, Mein-Woei and Wu, Yi-Cheng and Shiue, Yow-Ling and Su, Kuan-Pin},
title = {Omega-3 polyunsaturated fatty acids in sarcopenia management: A network meta-analysis of randomized controlled trials},
journal = {Ageing Research Reviews},
year = {2023},
volume = {90},
pages = {102014},
doi = {10.1016/j.arr.2023.102014}
}
EUVIMED